A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting

Open Access

Peer-reviewed

Research Article

Mayer N. Fishman ,

* E-mail: Mayer.Fishman@moffitt.org

Affiliation H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America
⨯
Jin Tomshine,

Affiliation Blue Ocean Pharma LLC, Annandale, New Jersey, United States of America
⨯
William J. Fulp,

Affiliation H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America
⨯
Pamela K. Foreman

Affiliation Blue Ocean Pharma LLC, Annandale, New Jersey, United States of America
⨯

Reader Comments (0)

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Renal cell carcinoma
Is the Subject Area "Renal cell carcinoma" applicable to this article?

Thanks for your feedback.
Phase III clinical investigation
Is the Subject Area "Phase III clinical investigation" applicable to this article?

Thanks for your feedback.
Cytokine therapy
Is the Subject Area "Cytokine therapy" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Renal cancer
Is the Subject Area "Renal cancer" applicable to this article?

Thanks for your feedback.
Database searching
Is the Subject Area "Database searching" applicable to this article?

Thanks for your feedback.